DK1104289T3 - Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister - Google Patents

Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister

Info

Publication number
DK1104289T3
DK1104289T3 DK99942892T DK99942892T DK1104289T3 DK 1104289 T3 DK1104289 T3 DK 1104289T3 DK 99942892 T DK99942892 T DK 99942892T DK 99942892 T DK99942892 T DK 99942892T DK 1104289 T3 DK1104289 T3 DK 1104289T3
Authority
DK
Denmark
Prior art keywords
agonists
antagonists
oral formulations
new oral
new
Prior art date
Application number
DK99942892T
Other languages
English (en)
Inventor
Christian Vitzling
Bruijn Karel De
Guenter Engel
Hans-Juergen Pfannkuche
Michael Thewissen
Othmar Zueger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1104289(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9818340.3A external-priority patent/GB9818340D0/en
Priority claimed from GBGB9823477.6A external-priority patent/GB9823477D0/en
Priority claimed from GBGB9910320.2A external-priority patent/GB9910320D0/en
Priority claimed from GBGB9911059.5A external-priority patent/GB9911059D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1104289T3 publication Critical patent/DK1104289T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK99942892T 1998-08-21 1999-08-19 Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister DK1104289T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9818340.3A GB9818340D0 (en) 1998-08-21 1998-08-21 Organic compounds
GBGB9823477.6A GB9823477D0 (en) 1998-10-27 1998-10-27 Organic compounds
GBGB9910320.2A GB9910320D0 (en) 1999-05-05 1999-05-05 Organic compounds
GBGB9911059.5A GB9911059D0 (en) 1999-05-12 1999-05-12 Organic compounds

Publications (1)

Publication Number Publication Date
DK1104289T3 true DK1104289T3 (da) 2006-05-15

Family

ID=27451823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99942892T DK1104289T3 (da) 1998-08-21 1999-08-19 Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister

Country Status (30)

Country Link
US (4) US20030236183A1 (da)
EP (1) EP1104289B1 (da)
JP (1) JP4048024B2 (da)
KR (1) KR100529659B1 (da)
CN (2) CN1165293C (da)
AT (1) ATE316782T1 (da)
AU (4) AU762829B2 (da)
BG (1) BG65322B1 (da)
BR (1) BR9913135A (da)
CA (1) CA2338794C (da)
CZ (1) CZ300647B6 (da)
DE (1) DE69929703T2 (da)
DK (1) DK1104289T3 (da)
EE (1) EE05054B1 (da)
ES (1) ES2257869T3 (da)
FR (3) FR2782454B1 (da)
HK (1) HK1038179A1 (da)
HR (1) HRP20010123B1 (da)
HU (1) HU228179B1 (da)
ID (1) ID28510A (da)
IL (1) IL141236A0 (da)
IS (1) IS2369B (da)
IT (1) IT1314185B1 (da)
NO (1) NO328756B1 (da)
NZ (1) NZ509832A (da)
PL (2) PL200132B1 (da)
RS (1) RS50104B (da)
SK (1) SK285255B6 (da)
TR (3) TR200400187T2 (da)
WO (1) WO2000010526A2 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270304A1 (en) 2000-07-07 2002-01-21 The Administrators Of The Tulane Educational Fund Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
EP1347779A2 (en) * 2000-11-24 2003-10-01 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
EP1598074B1 (en) 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
AU2006317530B2 (en) 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
AU2010313785C1 (en) 2009-10-30 2019-04-11 Ix Biopharma Ltd Fast dissolving solid dosage form
JP2014524293A (ja) 2011-08-20 2014-09-22 アドバンスド メディカル バルーンズ ゲーエムベーハー 経肛門的流入カテーテル及び反射作用を調整した排便を断続的に誘引する方法
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552398A (en) * 1895-12-31 Riveting-machine
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
ATE123237T1 (de) * 1990-08-24 1995-06-15 Spirig Ag Verfahren zur herstellung von pellets.
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
TW270114B (da) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5399562A (en) * 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
AU690417B2 (en) * 1994-12-01 1998-04-23 Amarin Development Ab Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
FR2753196B1 (fr) * 1996-09-12 1998-10-23 Synthelabo Derives d'indazole tricyclique, leur preparation et leur application en therapeutique
US6475510B1 (en) * 1997-12-19 2002-11-05 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod

Also Published As

Publication number Publication date
FR2784899B1 (fr) 2001-08-17
IS2369B (is) 2008-06-15
JP4048024B2 (ja) 2008-02-13
US20080075773A1 (en) 2008-03-27
US20030236183A1 (en) 2003-12-25
CN1323200A (zh) 2001-11-21
FR2782454A1 (fr) 2000-02-25
HUP0103431A2 (hu) 2002-01-28
CN1165293C (zh) 2004-09-08
BG105257A (en) 2001-11-30
WO2000010526A2 (en) 2000-03-02
US20120071537A1 (en) 2012-03-22
FR2782454B1 (fr) 2005-12-02
AU2006200048A1 (en) 2006-02-02
KR100529659B1 (ko) 2005-11-21
ITMI991826A1 (it) 2001-02-19
HRP20010123A2 (en) 2002-02-28
IT1314185B1 (it) 2002-12-06
SK2432001A3 (en) 2001-09-11
EE200100104A (et) 2002-06-17
RS50104B (sr) 2009-01-22
CZ2001619A3 (en) 2001-05-16
IS5851A (is) 2001-01-20
HU228179B1 (en) 2013-01-28
IL141236A0 (en) 2002-03-10
TR200100361T2 (tr) 2001-06-21
AU762829B2 (en) 2003-07-03
FR2784899A1 (fr) 2000-04-28
JP2002523351A (ja) 2002-07-30
CZ300647B6 (cs) 2009-07-08
PL200132B1 (pl) 2008-12-31
NO20010863D0 (no) 2001-02-20
TR200400187T2 (tr) 2006-11-21
FR2799123B1 (fr) 2005-12-02
NZ509832A (en) 2003-11-28
US20130158092A1 (en) 2013-06-20
NO20010863L (no) 2001-03-26
PL194069B1 (pl) 2007-04-30
DE69929703D1 (de) 2006-04-13
ITMI991826A0 (it) 1999-08-19
YU8701A (sh) 2003-12-31
DE69929703T2 (de) 2007-02-22
FR2799123A1 (fr) 2001-04-06
CA2338794A1 (en) 2000-03-02
EP1104289A2 (en) 2001-06-06
ES2257869T3 (es) 2006-08-01
EE05054B1 (et) 2008-08-15
AU5623299A (en) 2000-03-14
NO328756B1 (no) 2010-05-03
HRP20010123B1 (en) 2010-11-30
HK1038179A1 (en) 2002-03-08
BR9913135A (pt) 2001-05-08
AU2009200403A1 (en) 2009-02-26
CA2338794C (en) 2009-01-20
ATE316782T1 (de) 2006-02-15
SK285255B6 (sk) 2006-09-07
ID28510A (id) 2001-05-31
EP1104289B1 (en) 2006-02-01
KR20010079668A (ko) 2001-08-22
TR200102259T2 (tr) 2002-06-21
PL346764A1 (en) 2002-02-25
HUP0103431A3 (en) 2002-02-28
CN1589906A (zh) 2005-03-09
AU2003248212A1 (en) 2003-10-30
BG65322B1 (bg) 2008-02-29
WO2000010526A3 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
RS49609B (sr) Stabilizovani antihistaminski sirup
BR9810495A (pt) Composição farmacêutica
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
FR2792529B1 (fr) Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
HRP20010764B1 (en) Prucalopride oral solution
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
SE9902742D0 (sv) New pharmaceutical formultion
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.
ECSP993104A (es) Nueva formulacion oral
CR6300A (es) Nueva formulacion oral